Senores Pharma Files Share Capital Audit Report for Q1 FY27

Senores Pharmaceuticals Limited has submitted its Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026, as per Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by Company Secretary Tapan Shah, confirms the company's capital structure, equity share position across NSDL, CDSL, and physical forms, and details demat activities. The issued equity share capital stands at 4,60,53,588 shares. The report indicates 65.03% held in dematerialized form in NSDL and 34.97% in CDSL, totaling 100% dematerialized shares. No differences were noted between issued and listed capital, and no changes in share capital were reported during the quarter.